drugset / Trial / NCT00216892

Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris

NCT00216892

Phase 4 Completed 1032 enrolled LEO Pharma
RandomizedParallel-groupDouble-blindTreatment

Summary

Patients with psoriasis vulgaris of the trunk and/or limbs are randomised to treatment with: 1. 4 weeks of ointment containing calcipotriol and betamethasone dipropionate followed by 8 weeks of calcipotriol cream 2. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of calcipotriol cream on weekdays/ (calcipotriol plus betamethasone dipropionate) ointment on weekends 3. 4 weeks of (calcipotriol plus betamethasone dipropionate) ointment followed by 8 weeks of vehicle of calcipotriol cream The objective is to compare the efficacy and safety of the different treatment regimens

Timeline

Start
2005-04
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Betamethasone Other / unclassified 0.5 unknown
Subject Calcipotriol Small molecule 50 unknown

Indications